Zhengye Biotechnology Holding Ltd
No enriched coverage for $ZYBT in the last 7 days.
No SEC Form 4 filings for $ZYBT in the last 30 days.
See all $ZYBT insider activity →U.S. stocks closed higher on Friday, with the Dow Jones up 0.83%, S&P 500 up 0.59%, and Nasdaq up 0.64%. Top performers included Amazon, Cisco, and Visa, while Verizon, 3M, and Home Depot declined. Moderna and Crown Castle also saw significant gains. Oil prices fell slightly, and gold futures rose. The CBOE Volatility Index decreased by 3.70%.
Eloxx Pharmaceuticals (ELOX) rose 20% after FDA cleared its Phase 2b trial for exaluren. Vogenx (VOGX) gained 14% post-IPO. Arcturus (ARCT) advanced 21% on pipeline updates. Zhengye (ZYBT) +7% after Nasdaq compliance. Greenwich (GLSI) +10% on extended lock-up. HeartSciences (HSCS) +8% after $1M investment. AC Immune (ACIU) +8% on Phase 1 data.
Zhengye Biotechnology Holding Limited (Nasdaq: ZYBT) said Nasdaq notified it on Aug. 5, 2026 that it regained compliance with the $1.00 minimum bid price requirement under Nasdaq Rule 5550(a)(2). Nasdaq previously flagged ZYBT for trading below $1.00 for 30 straight business days, but determined the bid was at or above $1.00 for the last 10 consecutive sessions from July 20 to Aug. 4.
Recent ZYBT coverage spans market movers, financial news and earnings.
Strong upside momentum is evident, but the article lacks the reason for the jump.
Compliance restores investor confidence and avoids delisting risk.
Regaining bid-price compliance reduces delisting risk, which can stabilize sentiment and lower near-term liquidity/financing concerns.
The stock’s move is tied to a delisting-compliance overhang, but the article does not specify a cure plan.
Zhengye Biotechnology faces potential delisting risk after receiving a Nasdaq notice for delayed filing. This development introduces uncertainty around the company's stock performance.
AlphAI scores every news story that mentions ZYBT with an AI model for sentiment and relevance, and aggregates insider trades from Zhengye Biotechnology Holding Ltd's SEC EDGAR Form 4 filings. Figures refresh continuously.
U.S. stocks closed higher on Friday, with the Dow Jones up 0.83%, S&P 500 up 0.59%, and Nasdaq up 0.64%. Top performers included Amazon, Cisco, and Visa, while Verizon, 3M, and Home Depot declined. Moderna and Crown Castle also saw significant gains. Oil prices fell slightly, and gold futures rose. The CBOE Volatility Index decreased by 3.70%.
3 min readEloxx Pharmaceuticals (ELOX) rose 20% after FDA cleared its Phase 2b trial for exaluren. Vogenx (VOGX) gained 14% post-IPO. Arcturus (ARCT) advanced 21% on pipeline updates. Zhengye (ZYBT) +7% after Nasdaq compliance. Greenwich (GLSI) +10% on extended lock-up. HeartSciences (HSCS) +8% after $1M investment. AC Immune (ACIU) +8% on Phase 1 data.
3 min readZhengye Biotechnology Holding Limited (Nasdaq: ZYBT) said Nasdaq notified it on Aug. 5, 2026 that it regained compliance with the $1.00 minimum bid price requirement under Nasdaq Rule 5550(a)(2). Nasdaq previously flagged ZYBT for trading below $1.00 for 30 straight business days, but determined the bid was at or above $1.00 for the last 10 consecutive sessions from July 20 to Aug. 4.
3 min readBiotech gainers included Zhengye Biotechnology (ZYBT), up about 1,048% after a Nasdaq bid-price noncompliance notice. Advanced Biomed (ADVB) rose over 70% after withdrawing a planned SEC-registered offering. Neuronetics (STIM) gained after naming a new CFO. Armata Pharmaceuticals (ARMP) advanced on Phase 3 AP-SA02 progress. Other movers: Profusa (PFSA), Ridgetech (RDGT), Turn Therapeutics (TTRX).
6 min readZhengye receives a Nasdaq notice for failing to file its 2024 annual report on time. The company has 60 days to submit a compliance plan to avoid potential delisting. Get access to the leaderboards pointing to tomorrow's biggest stock movers.
2 min readJilin, China, May 23, 2025 ( GLOBE NEWSWIRE ) -- Zhengye Biotechnology Holding Limited ( Nasdaq: ZYBT ) ( the "Company" or "Zhengye" ) , a veterinary vaccine manufacturer that encompasses research, development, manufacturing, and sales of veterinary vaccines, with a focus on livestock vaccines ...
2 min read